ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Rating) – Research analysts at Cantor Fitzgerald lifted their FY2022 earnings per share estimates for ALX Oncology in a report released on Tuesday, May 10th. Cantor Fitzgerald analyst L. Watsek now expects that the company will post earnings of ($2.69) per share for the year, up from their previous forecast of ($3.31). Cantor Fitzgerald has a “Overweight” rating on the stock.
ALX Oncology (NASDAQ:ALXO – Get Rating) last posted its quarterly earnings data on Monday, May 9th. The company reported ($0.60) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.71) by $0.11.
Shares of NASDAQ:ALXO opened at $8.58 on Thursday. The stock has a market capitalization of $349.04 million, a P/E ratio of -4.17 and a beta of 2.64. ALX Oncology has a 1-year low of $8.47 and a 1-year high of $81.19. The firm’s 50 day moving average price is $16.28.
Institutional investors and hedge funds have recently bought and sold shares of the business. Invesco Ltd. lifted its holdings in ALX Oncology by 6,841.9% during the third quarter. Invesco Ltd. now owns 514,815 shares of the company’s stock valued at $38,024,000 after purchasing an additional 507,399 shares in the last quarter. Wellington Management Group LLP lifted its holdings in ALX Oncology by 33.5% during the third quarter. Wellington Management Group LLP now owns 3,867,142 shares of the company’s stock valued at $285,627,000 after purchasing an additional 970,252 shares in the last quarter. Goldman Sachs Group Inc. lifted its holdings in ALX Oncology by 19.6% during the third quarter. Goldman Sachs Group Inc. now owns 162,996 shares of the company’s stock valued at $12,039,000 after purchasing an additional 26,663 shares in the last quarter. Pier Capital LLC purchased a new position in ALX Oncology during the third quarter valued at $5,566,000. Finally, Russell Investments Group Ltd. lifted its holdings in ALX Oncology by 36.6% during the fourth quarter. Russell Investments Group Ltd. now owns 41,430 shares of the company’s stock valued at $889,000 after purchasing an additional 11,099 shares in the last quarter. 89.42% of the stock is currently owned by institutional investors and hedge funds.
About ALX Oncology (Get Rating)
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for patients fighting cancer. Its lead product candidate is ALX148, a CD47 blocking therapeutic that is in Phase 1b/2 clinical trial used for the treatment of myelodysplastic syndromes; and for the treatment of acute myeloid leukemia and non-Hodgkin's lymphoma, as well as a range of solid tumor indications, including head and neck squamous cell carcinoma, human epidermal growth factor receptor 2 (HER2) positive gastric/gastroesophageal junction carcinoma, HER2-expressing breast cancer, and other solid tumors.
- Get a free copy of the StockNews.com research report on ALX Oncology (ALXO)
- Corning Stock is a Technology Value Play
- Anheuser-Busch InBev May Need One More Quarter to Confirm a Buy Signal
- Wolverine Worldwide Is Ready To Rebound
- Wendy’s Growth Story Has Come To An End
- Can Six Flags(SIX) or Cedar Fair (FUN) Give Investors a Thrill Later This Year?
Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.